Follow The Filings

INSM Insmed Inc.

Health Care, filed as INSMED INC (COM PAR $.01), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 2 managers in 2026 Q2, sold by 1

  • 4 Owners
  • Max 6.1%
  • $426M
  • 1 new 1 add 1 reduce 1 small

In 2026 Q2 Lee Ainslie opened a position in Insmed, Stanley Druckenmiller added, and Ron Baron trimmed.

Who owns this now

Largest portfolio weights among holders, up to 6.1% (Palo Alto Investors). Not free-float ownership.

  1. Palo Alto Investors Reduce 6.1%
  2. Stanley Druckenmiller Add 2.9%
  3. Lee Ainslie New 2.0%

Who owns INSM

Sorted by value, long equity only, as of 2026 Q2.

History
Lee Ainslie, Maverick Capital 2.0% New 2.0% 2,150,762 $229M History
Stanley Druckenmiller, Duquesne Family Office 2.9% Add +23.4% 1,424,690 $152M History
Palo Alto Investors 6.1%, was 10.4% Small trim −0.3% 413,980 $44M History
Ron Baron, Bamco Inc. (Baron Capital) <0.01%, was 0.01% Reduce −50.0% 10,000 $1.1M History

4 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by INSM's executives, directors and 10% owners in the last 12 months, from their Form 4s

All INSM insider trades
  • None no insider bought on the open market
  • $63.3M sold by 6 insiders outside a trading plan
  • $92M sold by 5 insiders under 10b5-1 plans
  1. David R Brennan Director
    Sale
    $3.1M 25,000 shares at $124.00 39% of stake
    Traded Sep 9 Filed Sep 11
    ↗
  2. Melvin Sharoky MD Director
    Sale
    $638K 5,000 shares at $127.53 100% of stake
    Traded Aug 17 Filed Aug 19
    ↗
  3. Roger Adsett COO
    Sale
    $32M 239,850 shares at $133.27 71% of stake
    Traded Aug 10 Filed Aug 12
    ↗
  4. Martina Flammer M.D. Chief Medical Officer
    Planned sale
    $3.5M 27,173 shares at $128.61 31% of stake
    Traded Aug 6 Filed Aug 7
    ↗
  5. William Lewis CEO
    Planned sale
    $1.1M 10,700 shares at $106.06 4% of stake
    Traded Jul 23 Filed Jul 24
    ↗
  6. William Lewis CEO
    Planned sale
    $1.3M 10,699 shares at $117.40 4% of stake
    Traded Jul 9 Filed Jul 10
    ↗
  7. Martina Flammer M.D. Chief Medical Officer
    Planned sale
    $1.4M 12,302 shares at $109.98 17% of stake
    Traded Jul 6 Filed Jul 8
    ↗
  8. William Lewis CEO
    Planned sale
    $2.2M 21,398 shares at $103.32 7.6% of stake
    Traded Jun 25 Filed Jun 26
    ↗
  9. Michael Alexander Smith Chief Legal Officer
    Planned sale
    $173K 1,806 shares at $95.82 4.6% of stake
    Traded Jun 22 Filed Jun 24
    ↗
  10. William Lewis CEO
    Planned sale
    $613K 6,515 shares at $94.03 2.5% of stake
    Traded Jun 8 Filed Jun 10
    ↗
  11. Martina Flammer M.D. Chief Medical Officer
    Planned sale
    $193K 1,858 shares at $103.78 3% of stake
    Traded Jun 5 Filed Jun 5
    ↗
  12. Michael Alexander Smith Chief Legal Officer
    Planned sale
    $667K 6,149 shares at $108.47 13% of stake
    Traded May 22 Filed May 22
    ↗
  13. William Lewis CEO
    Planned sale
    $2.7M 25,564 shares at $106.33 8.6% of stake
    Traded May 18 Filed May 20
    ↗
  14. Martina Flammer M.D. Chief Medical Officer
    Planned sale
    $1.2M 10,479 shares at $117.54 14% of stake
    Traded May 14 Filed May 15
    ↗
  15. Martina Flammer M.D. Chief Medical Officer
    Planned sale
    $1.3M 12,949 shares at $100.40 14% of stake
    Traded May 11 Filed May 13
    ↗

Also filed in the last 12 months, not counted as buying or selling: 52 option exercises, 31 sales to cover taxes, 17 stock grants, and 11 gifts.

Congress

2 members of Congress traded INSM in the last three years: 1 buy and 8 sales. 2 members listed it in 2025 annual reports.

All Congress trades
  1. Josh Gottheimer D-NJ-5Joint Partial sale $1K–$15K Jun 10 filed Jul 7
  2. Gilbert Ray Cisneros, Jr. D-CA-31 Sell $1K–$15K Oct 3, 2025 filed Nov 18, 2025
  3. Gilbert Ray Cisneros, Jr. D-CA-31 Partial sale $1K–$15K Sep 22, 2025 filed Oct 10, 2025
  4. Gilbert Ray Cisneros, Jr. D-CA-31 Partial sale $1K–$15K Aug 8, 2025 filed Sep 12, 2025
  5. Gilbert Ray Cisneros, Jr. D-CA-31 Partial sale $1K–$15K Jul 7, 2025 filed Aug 14, 2025
  6. Josh Gottheimer D-NJ-5Joint Buy $1K–$15K Jun 16, 2025 filed Jul 16, 2025

SEC filings

Recent issuer filings from EDGAR, 11 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 1 day ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $305.21M $363.71M $606.42M
Gross profit * $239.64M $277.96M $483.48M
Gross margin * 78.5% 76.4% 79.7%
Net income -$0.75B -$0.914B -$1.28B
Net margin * -245.6% -251.2% -210.5%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $0.929B $1.62B $1.79B
Total non-current assets * $400.77M $403.57M $470.35M
Total assets $1.33B $2.03B $2.26B
Total current liabilities $225.63M $297.53M $468.87M
Total non-current liabilities * $1.44B $1.44B $1.06B
Total equity -$331.92M $285.38M $738.98M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$536.25M -$683.88M -$935.01M
Cash from investing -$223.6M -$583.18M -$64.58M
Cash from financing $0.168B $1.34B $0.954B
Net change in cash -$591.66M $72.66M -$44.58M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.